Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsFoundations — research methods and study design

Psych MEQs / SAQs · Foundations — research methods and study design

Choosing and defending study designs in psychiatry (MEQ)

FRANZCP/MRCPsych-style MEQ on design–question matching, bias threats, and CONSORT/STROBE/COREQ reporting for psychiatry research scenarios.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar designing (or advising on) three separate research questions for a departmental academic meeting. (A) Does adjunctive CBT reduce 6-month relapse compared with medication management alone in adults with remitted major depression? (B) Among people starting clozapine, what is the incidence of severe neutropenia over 12 months, and which baseline factors predict it? (C) What are the lived experiences of Aboriginal and Torres Strait Islander carers supporting a relative with first-episode psychosis? For each question: (i) name the most appropriate primary study design and justify the match; (ii) name the single most important structural validity threat if methods are weak; (iii) name the most relevant reporting guideline. Finally, (iv) explain in three to four sentences why an RCT is not the default answer for questions B and C. (20 marks)

Model answer

Reveal model answer

(A) CBT adjunct for relapse prevention. (i) Parallel-group RCT (ideally assessor-blind; full double-blind of therapy content often impossible) randomising remitted adults to CBT plus medication management versus medication management alone, with pre-specified 6-month relapse as primary outcome.[1][3] (ii) Main threats if weak: performance/detection bias (unblinded supportive contact and unblinded relapse ratings) and attrition with completer-only analysis.[3] (iii) CONSORT for trial reporting (flow, randomisation, outcomes).[3]

(B) Clozapine severe neutropenia incidence and predictors. (i) Prospective cohort of new clozapine starters with active haematological surveillance — exposure defined at inception, outcomes counted forward to estimate incidence and associations with baseline predictors.[2] A case-control design could study rare agranulocytosis associations but does not directly yield incidence without a defined source population and sampling fraction.[1] (ii) Main threats: loss to follow-up, incomplete blood monitoring data, and confounding of predictors (comorbidity, co-prescribing).[6][2] (iii) STROBE (cohort checklist).[4]

(C) Carer lived experience. (i) Qualitative design (e.g. semi-structured interviews with purposive sampling; thematic analysis or culturally adapted methodology with Indigenous governance).[5] (ii) Main threats: poor reflexivity, tokenistic sampling, analysis without credibility checks, extracting themes as if they were prevalence rates.[5] (iii) COREQ for interview/focus-group reporting.[5]

(iv) Why RCT is not default for B and C. Question B asks for incidence and predictors under real-world clozapine use, not experimental assignment of a harmful outcome; randomising people to clozapine solely to count neutropenia would be unethical and unnecessary when the exposure is already indicated clinically — a cohort matches the question.[2][1] Question C asks for meaning and experience, which quantitative trials do not answer; forcing an RCT would be a design–question mismatch.[5][1] Hierarchy rank does not override question fit or ethics.

Common errors

Defaulting every question to RCT; calling a monitoring programme a case-control study; using CONSORT for qualitative work; equating COREQ with quality of insight; claiming cohorts cannot estimate incidence; ignoring Indigenous research governance for question C.[1][3][4][5]

References

  1. [1]Grimes DA, Schulz KF An overview of clinical research: the lay of the land Lancet, 2002.PMID 11809203
  2. [2]Grimes DA, Schulz KF Cohort studies: marching towards outcomes Lancet, 2002.PMID 11830217
  3. [3]Schulz KF, Altman DG, Moher D; CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials BMJ, 2010.PMID 20332509
  4. [4]von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Lancet, 2007.PMID 18064739
  5. [5]Tong A, Sainsbury P, Craig J Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups Int J Qual Health Care, 2007.PMID 17872937
  6. [6]Grimes DA, Schulz KF Bias and causal associations in observational research Lancet, 2002.PMID 11812579